104 results about "Muscarinic receptor site" patented technology

The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M₃ agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

M₃ Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

This invention relates to compounds, compositions, and methods useful for modulating cholinergic muscarinic receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of cholinergic muscarinic receptor genes, such as M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Novel thiazole aniline compounds, pharmaceutical compositions, methods of making them and uses thereof in treating M₃ muscarinic acetylcholine receptor mediated diseases are disclosed.

The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

The present invention is directed to novel Muscarinic Acetylcholine receptor antagonists of Formula (I), pharmaceutical compositions and methods of using them. Compounds of Formula (I) are, inter alia,

wherein:

• R1 and R2 are, independently, selected from the group consisting of

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.